ArticleFuture oncology (London, England)2021
Increasing access to quality anticancer medicines in low- and middle-income countries: the experience of Uganda.
Article in Future oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global, regional and national availability of essential medicines for children, 2009-2020: a systematic review and meta-analysis.BMC public health · 2023Pooled it
- Outpatient reimbursement policies for cancer treatment in China: a comparative and longitudinal analysis.BMC health services research · 2026Article
- Access to cancer medicines in Kenya: a scoping review of costs, financial toxicity, quality of life and policy impacts.Ecancermedicalscience · 2026Review
- Barriers to accessing high-quality cancer medicines in Cameroon. A qualitative study of the views and practices of regulators and frontline healthcare providers.PLOS global public health · 2026Article
- A novel social-network-analysis-based approach for analyzing complex network of actors involved in accessibility of anti-cancer medications in Iran.Health research policy and systems · 2024Article
- Article
- Listening to Patient and Caregiver Voices to Anchor Global Cancer Control.Journal of cancer education : the official journal of the American Association for Cancer Education · 2023Article
- Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa: Examples from Kenya, Rwanda, and Uganda.The oncologist · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cancer is one of the leading causes of death with 9.6 million deaths registered in 2018, of which 70% occur in Africa, Asia and Central and South America, the low-and middle-income countries (LMICs). The global annual expenditure on anticancer medicines increased from $96 billion in 2013 to $133 billion in 2017. This growth rate is several folds that of newly diagnosed cancer cases and therefore estimated to reach up to $200 billion by 2022. The Uganda Cancer Institute, Uganda's national referral cancer center, has increased access to cancer medicines through an efficient and cost-saving procurement system. The system has achieved cost savings of more than USD 2,000,000 on a total of 37 of 42 essential cancer medicines. This has resulted in 85.8% availability superseding the WHO's 80% target. All selected products were procured from manufacturers with stringent regulatory authority approval or a proven track record of quality products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.